Genmab Licenses Preclinical-Stage Antibody to Serono
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 60 (Table of Contents)
Published: 5 Jun-2005
DOI: 10.3833/pdr.v2005.i60.670 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Genmab granted Serono the exclusive worldwide rights to develop and commercialize a preclinical candidate HUMax-Tac useful for treating various T-cell mediated diseases including autoimmune disorders, inflammatory and hyperproliferative skin disorders and acute transplant rejection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS